Type 2 diabetes: what AU general practice actually does in 2026

What type 2 diabetes actually is

Type 2 diabetes (T2DM) is a chronic condition with two underlying problems: the body’s tissues become less responsive to insulin (insulin resistance), and the pancreas progressively struggles to make enough insulin to compensate (β-cell decline). The result is sustained high blood glucose, which over years damages small blood vessels (eyes, kidneys, nerves) and accelerates large-vessel disease (heart, brain, peripheral arteries).

Roughly 5% of Australian adults are diagnosed, with another 25% in the pre-diabetes range — significantly more if undiagnosed cases are included. The condition is markedly more common in Aboriginal and Torres Strait Islander Australians (3–4× higher prevalence, earlier onset), South Asian and Pacific Islander Australians, and people with strong family history.

The good news that has changed substantially in the last decade: T2DM is increasingly treatable, several classes of medication produce benefits well beyond glucose lowering, and meaningful remission is achievable for some patients — especially within the first five years after diagnosis.

A. Core clinical — diagnosis and the AU general practice framework

Diagnosis

Per Therapeutic Guidelines and the 2024 RACGP / Diabetes Australia handbook, diagnosis is confirmed by any one of:

Test	Diabetes threshold
HbA1c	≥6.5% (48 mmol/mol)
Fasting plasma glucose	≥7.0 mmol/L
Random plasma glucose with classic symptoms	≥11.1 mmol/L
2-hour OGTT (75g load)	≥11.1 mmol/L

A single unequivocal result with symptoms confirms; otherwise the test is repeated on a different day. Pre-diabetes sits between normal and diabetes thresholds and is a strong predictor of progression — and a strong opportunity for prevention.

What your GP will likely do at diagnosis

A new T2DM diagnosis warrants a structured initial workup:

• HbA1c to establish a baseline severity
• Fasting lipids, UEC + eGFR + urine albumin-creatinine ratio (UACR), LFTs, TSH, B12 (long-term metformin can lower B12), ferritin in selected cases
• Foot exam — sensation with 10g monofilament, vibration, reflexes, peripheral pulses, skin integrity. Annual minimum from diagnosis.
• Eye assessment — referral for retinal photography or ophthalmology review. Australia has a national reminder system at KeepSight.
• ECG and calculated cardiovascular risk via the Heart Foundation calculator
• Mental-health screen — about 30% of people with diabetes have co-existing depression or anxiety, with bidirectional effects on glycaemic control

The NDSS (National Diabetes Services Scheme) registration provides subsidised consumables and, for some patients, continuous glucose monitoring devices.

Targets

HbA1c target is individualised — there is no one number that fits everyone:

• ~7% (53 mmol/mol) for most adults
• ~6.5% in younger people without complications and at low risk of hypoglycaemia
• ≥8% in older or frail patients where the risks of overly tight control (falls, hypoglycaemia) exceed the long-term complication risk reduction. This shifted significantly after the ACCORD trial (NEJM 2008) showed harm from very tight glycaemic targets in high-risk older adults.

Beyond glucose: BP under 130/80 with established complications, high-intensity statin in those at high cardiovascular risk, antiplatelet therapy only for secondary prevention. Targets are reviewed annually.

B. Evidence appraisal — what’s changed in the last decade

The cardiovascular outcome trials. Starting with EMPA-REG OUTCOME (NEJM 2015), a series of randomised trials demonstrated that the newer glucose-lowering classes — SGLT2 inhibitors and GLP-1 receptor agonists — reduce cardiovascular events, heart failure hospitalisations, and (with the SGLT2i class specifically) progression of chronic kidney disease. The benefit is largely independent of glucose lowering, suggesting these drugs are doing something else mechanistically — natriuresis, intra-renal haemodynamics, weight loss, anti-inflammatory effects.

For most patients with T2DM and any of: established cardiovascular disease, heart failure, chronic kidney disease, or obesity, an SGLT2i or GLP-1 RA is now the preferred second agent over older options (sulfonylureas, pioglitazone). This is reflected in the Australian T2DM management algorithm.

The remission story — DiRECT. The Lean et al. Lancet 2018 trial demonstrated that intensive weight management in general practice, driving ≥15 kg weight loss, put about half of participants into T2DM remission at 12 months — a third remained in remission at 5 years. The mechanism is reversal of pancreatic and hepatic fat infiltration (‘twin cycle’ theory). This is realistic for many patients in the first 5 years of diagnosis.

Mediterranean / DASH pattern. Consistently outperforms calorie-counting alone in the long term. Cardiovascular event reduction is on top of glucose benefit.

Mounjaro / tirzepatide. PBS listing declined April 2026 — remains private-prescription only in Australia. Approximately AUD $400–500/month at full private price. TGA December 2024 updated contraception advice (reduced oral contraceptive efficacy in first 4 weeks of treatment and after dose increases).

What hasn’t held up. Routine intensive glucose lowering toward HbA1c under 6.5% across the board — ACCORD showed harm in older high-risk patients. Aspirin for primary prevention in T2DM without established CVD — ASCEND (NEJM 2018) showed bleeding harms balanced cardiovascular benefit. Beta-blockers as routine antihypertensive in uncomplicated T2DM — no longer first-line.

C. Australian operations — what the visit looks like

The AU pathway integrates several MBS items per the Department of Health:

• Long consultations (items 36 or 44) for the annual review and treatment-intensification conversations
• GP Chronic Conditions Management Plan (GPCCMP) — replaced 721/723/732 from 1 July 2025. T2DM is the prototypical chronic condition for this pathway. Opens up to 5 subsidised allied-health visits per calendar year (10 for ATSI patients): dietitian, exercise physiologist, podiatrist, credentialled diabetes educator, optometrist
• Heart Health Check (item 699) — annual cardiovascular review for all eligible adults
• 75+ Health Assessment (item 705) — comprehensive review including diabetes management
• 45–49 Health Assessment (item 701) — opportunity to identify pre-diabetes early
• Practice nurse follow-up (item 10997) — supports between-doctor reviews
• Mental Health Treatment Plan (item 2715 or 2717) — for the ~30% with co-existing depression or anxiety
• NDSS registration — subsidised consumables; CGM eligibility for some patients

(MBS / PBS items verified 2026-05-18 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

For Aboriginal and Torres Strait Islander patients: the ATSI Health Assessment (item 715) is annual and opens 10 allied-health visits per calendar year — recognising both higher prevalence and earlier onset.

D. Integrative and lifestyle considerations

Where lifestyle interventions have AU primary-tier evidence in T2DM:

Intervention	Effect	Quality of evidence
5–10% weight loss	HbA1c reduction 0.5–1%; substantial in first 5 years; can drive remission	Strong (DiRECT, Look AHEAD)
Mediterranean / DASH dietary pattern	HbA1c reduction 0.3–0.7%; cardiovascular event reduction independent of glucose	Strong
150 min/week moderate aerobic + 2 resistance sessions	HbA1c reduction 0.5–0.7%; cardiovascular benefit	Strong
Low-carbohydrate eating	Significant short-term HbA1c reduction; long-term adherence variable	Moderate
Intermittent fasting (5:2 or TRE)	Comparable to standard energy restriction at matched intake	Moderate (detailed in the IF post)
Bariatric surgery in BMI ≥35 + complications	High remission rates; durable in many	Strong
Berberine	Modest HbA1c lowering in small trials; lacks regulatory standardisation	Weak
Cinnamon, chromium, alpha-lipoic acid	Mixed evidence; not first-line	Weak
Continuous glucose monitoring (CGM)	Improves time-in-range and motivation; PBS-restricted in T2DM	Moderate-strong in selected populations

The pattern: lifestyle first, weight is the highest-leverage variable, dietary pattern matters more than counting individual nutrients, and supplements are not where the real gains live.

When to seek help sooner rather than later

Specific T2DM symptoms or contexts that warrant prompt review or emergency care:

• Diabetic ketoacidosis (DKA) — abdominal pain, dyspnoea, vomiting, breath of acetone, positive urine ketones (or strip-detected blood ketones). Includes euglycaemic DKA on SGLT2i where blood glucose can be near-normal but ketones are positive — call 000 / go to ED.
• Hyperglycaemic hyperosmolar state (HHS) — typically elderly, glucose often >30 mmol/L, dehydration, altered conscious state. Emergency.
• Severe hypoglycaemia with confusion, loss of consciousness, or unable to self-treat — call 000.
• Sudden vision change — macular oedema, vitreous haemorrhage, neovascularisation. Urgent ophthalmology.
• Foot ulcer, especially with signs of infection (redness, warmth, discharge, fever) — same-day GP or ED depending on severity.
• Rapid kidney function decline detected on bloods.
• Pregnancy or planning pregnancy — pre-conception planning is important; teratogenic medications (statins, ACEi/ARB, SGLT2i, GLP-1 RA) need to be stopped before conception and the regimen converted to insulin where appropriate.

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — the RACGP / Diabetes Australia 2024 handbook, Therapeutic Guidelines, Australian Medicines Handbook, NPS MedicineWise, and the major cardiovascular outcome trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific medications, targets, and the timing of escalations are made with your own GP and treating clinicians.

For Australian consumer-friendly sources: Diabetes Australia, HealthDirect — Type 2 diabetes, Better Health Channel, NDSS.

---

Sources cited

1. RACGP / Diabetes Australia 2024 handbook
2. Therapeutic Guidelines (eTG) — Diabetes
3. Australian Medicines Handbook
4. NPS MedicineWise
5. Diabetes Australia
6. NDSS
7. Heart Foundation — CVD guideline 2023
8. KeepSight
9. HealthDirect
10. Better Health Channel
11. AIHW — Diabetes
12. Lean MEJ et al. — DiRECT trial (Lancet 2018)
13. Zinman B et al. — EMPA-REG (NEJM 2015)
14. Marso SP et al. — LEADER (NEJM 2016)
15. Heerspink HJL et al. — DAPA-CKD (NEJM 2020)